Skip to main content

Table 2 Dose modifications for continuous dosing temozolomide

From: ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial

Toxicity

Withhold TMZ (until counts return to above criteria)

TMZ discontinuation

ANC

0.5 and < 1.5 x 109/l

< 0.5 x 109/l

Platelets

10 and < 100 x 109/l

< 10 x 109/l

CTCAE toxicity (version 5)

Grade 2

Grade 3-4

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us